脂肪酸偶联放射性药物用于成纤维细胞活化蛋白靶向放射治疗
本研究将月桂酸(C12)和棕榈酸(C16)偶联至FAPI-04,得到白蛋白结合型放射性药物FAPI-C12和FAPI-C16,并用镓-68、钇-86和镥-177标记,系统评价其用于癌相关成纤维细胞靶向放射治疗的潜力。两种药物对成纤维细胞活化蛋白(FAP)具有高亲和力,血液循环时间延长、肿瘤摄取显著增强,其中镥-177标记的FAPI-C16在荷瘤模型中显示肿瘤体积抑制和生存期延长。
要点
- FAPI-C12和FAPI-C16对FAP的IC50分别为6.80±0.58 nM和5.06±0.69 nM。
- [177Lu]Lu-FAPI-C16在24 h和72 h的肿瘤摄取均高于[177Lu]Lu-FAPI-C12和[177Lu]Lu-FAPI-04。
- 高活度29.6 MBq的[177Lu]Lu-FAPI-C16组中位生存28天,长于[177Lu]Lu-FAPI-04组的10天。
核心结论
- 该概念验证研究验证了偶联白蛋白结合基团可改变FAPI类放射性药物的药代动力学并增强肿瘤摄取的假设,可能成为将诊断用FAP靶向放射性药物转化为治疗配对药物的通用策略。
研究设计与样本
- 将月桂酸(C12)和棕榈酸(C16)偶联至FAPI-04,得到FAPI-C12和FAPI-C16两种白蛋白结合型FAPI放射性药物。
- 用镓-68、钇-86和镥-177进行标记,开展稳定性研究、结合亲和力测定、PET和SPECT显像、生物分布及放射性核素治疗研究。
主要发现
- FAPI-C12和FAPI-C16对FAP的IC50分别为6.80±0.58 nM和5.06±0.69 nM,在生理盐水和血浆中均稳定。
- 先用FAPI-C16处理后,[68Ga]Ga-FAPI-04的肿瘤摄取至30 h下降56.9%。
- [86Y]Y-FAPI-C12和[86Y]Y-FAPI-C16在HT-1080-FAP肿瘤中的摄取均远高于HT-1080-Vehicle肿瘤,证实二者具有高FAP特异性。
- FAPI-C12和FAPI-C16的血液循环时间均明显长于FAPI-04,肿瘤摄取显著增强。
- [177Lu]Lu-FAPI-C16在24 h(11.22±1.18%IA/g)和72 h(6.50±1.19%IA/g)的肿瘤摄取均高于[177Lu]Lu-FAPI-C12(24 h为7.54±0.97%IA/g;72 h为2.62±0.65%IA/g),二者均远高于[177Lu]Lu-FAPI-04注射后24 h的1.24±0.54%IA/g。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Radiopharmaceuticals that target cancer-associated fibroblasts (CAFs) have become an increasingly attractive strategy for cancer theranostics. Recently, a series of fibroblast activation protein inhibitor (FAPI)-based radiopharmaceuticals have been successfully applied to the diagnosis of a variety of cancers and exhibited excellent tumor selectivity. Nevertheless, CAF-targeted radionuclide therapy encounters difficulties in cancer treatment, as the tumor uptake and retention of FAPIs are insufficient. To meet this challenge, we tried to conjugate albumin-binding moiety to FAPI molecule for prolonged circulation that may increase the accumulation and retention of radiopharmaceuticals in tumor. METHODS: Two fatty acids, lauric acid (C12) and palmitic acid (C16), were conjugated to FAPI-04 to give two albumin-binding FAPI radiopharmaceuticals, denoted as FAPI-C12 and FAPI-C16, respectively. They had been radiolabeled with gallium-68, yttrium-86, and lutecium-177 for stability study, binding affinity assay, PET and SPECT imaging, biodistribution, and radionuclide therapy study to systematically evaluate their potential for CAF-targeted radionuclide therapy. RESULTS: FAPI-C12 and FAPI-C16 showed high binding affinity to FAP with the IC50 of 6.80 ± 0.58 nM and 5.06 ± 0.69 nM, respectively. They were stable in both saline and plasma. The tumor uptake of [68Ga]Ga-FAPI-04 decreased by 56.9% until 30 h after treated with FAPI-C16 before, and the uptakes of [86Y]Y-FAPI-C12 and [86Y]Y-FAPI-C16 in HT-1080-FAP tumor were both much higher than that of HT-1080-Vehicle tumor which identified the high FAP specific of these two radiopharmaceuticals. Both FAPI-C12 and FAPI-C16 showed notably longer circulation and significantly enhanced tumor uptake than those of FAPI-04. [177Lu]Lu-FAPI-C16 had the higher tumor uptake at both 24 h (11.22 ± 1.18%IA/g) and 72 h (6.50 ± 1.19%IA/g) than that of [177Lu]Lu-FAPI-C12 (24 h, 7.54 ± 0.97%IA/g; 72 h, 2.62 ± 0.65%IA/g); both of them were much higher than [177Lu]Lu-FAPI-04 with the value of 1.24 ± 0.54%IA/g at 24 h after injection. Significant tumor volume inhibition of [177Lu]Lu-FAPI-C16 at the high activity of 29.6 MBq was observed, and the median survival was 28 days which was much longer than that of the [177Lu]Lu-FAPI-04 treated group of which the median survival was only 10 days. CONCLUSION: This proof-of-concept study validates the hypothesis that conjugation of albumin binders may shift the pharmacokinetics and enhance the tumor uptake of FAPI-based radiopharmaceuticals. This could be a general strategy to transform the diagnostic FAP-targeted radiopharmaceuticals into their therapeutic pairs.
引用
- Zhang P, Xu M, Ding J, et al. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy. Eur J Nucl Med Mol Imaging. 2021. PMID: 34746969. doi:10.1007/s00259-021-05591-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。